2023年6月4日,

髓治療,臨床分期mRNA-immunotherapy公司——宣布完成了7300萬美元的資金由Hatteras新投資者的投資合作夥伴參與拱Venture Partners和摩爾的戰略投資。所有現有的投資者,包括Newpath夥伴,8風險投資,風險投資,和亞曆山大也參加了。所得資金將支持繼續mt - 101的臨床發展,骨髓的細胞療法項目階段1/2 T細胞淋巴瘤,並將加快發展mt - 302,一個first-in-class TROP2-FcA mRNA-LNP產品,為TROP2-expressing腫瘤1/2研究階段。和額外的體內編程候選人也推進診所。mt - 302:從公司的專有ATAK汽車受體圖書館,骨髓的小說體內工程平台具體目標和激活骨髓細胞引起更廣泛的抗腫瘤獲得性免疫。通過這種方法,骨髓表明交付lipid-nanoparticles (lnp)封裝mRNA的結果由髓細胞體內吸收和選擇性表達,導致有效的腫瘤死亡在多個冷腫瘤模型。公司的領導體內程序mt - 302是一個TROP2-targeting體內骨髓內艙車專為表達式。和TROP2腫瘤相關抗原表達廣泛上皮腫瘤,包括一些最難治性癌症。mt - 302表明單一療法治療活動TROP2 / TNBC模型,確定程序的效力髓細胞在T細胞的缺失。骨髓相信mt - 302 TROP2-ADC方法相比有明顯優勢通過其進行完整的免疫反應的能力。 In 2023, Myeloid expects to initiate a Phase 1/2 clinical study with MT-302 for patients with TROP2-expressing tumors. MT-101: MT-101 is the company’s first autologous CAR monocyte. And this candidate was derived from the Company’s proprietary ATAK platform and designed to harness the ability of myeloid cells to penetrate into tumors and promote broad anti-tumor activity. Plus MT-101 targets CD5, a surface receptor that is present in greater than 75% of peripheral T cell lymphomas. To create MT-101, the patient’s cells are engineered ex vivo with the mRNA-strand coding for the CAR. The engineered cells are delivered back to the patient within a vein-to-vein time of eight days. The ATAK CAR is proprietary to Myeloid and manufactured using the Company’s patented processes. The IMAGINE study (NCT05138458) is a Phase 1/2, multicenter, open-label, first-in-human, multiple ascending dose study to evaluate MT-101 in patients with refractory or relapsed PTCL and CTCL. The dose-escalation portion of this study, conducted with and without conditioning therapy, is open and enrolling patients. RetroT: Retrotransposons are genetic elements that replicate through reverse transcription of an RNA transposition intermediate. And retrotransposons contribute to structural changes and more importantly, to gene regulation. Myeloid’s RetroT technology relies on a single-strand mRNA to deliver genetic sequences and integration enzymes. This breakthrough technology offers the potential to deliver gene-sized pieces of DNA into the genome in a virus-free manner. And the payload realizable with RetroT is larger than currently possible with all known existing gene editing technologies. As a result, the company’s RetroT platform holds the potential to significantly expand the type and scope of genetic errors that can be reversed in situ. In March 2022, Myeloid entered into an exclusive option and research collaboration agreement with Prime Medicine to develop and accelerate RetroT. KEY QUOTES: “Myeloid continues to make significant progress across all aspects of our business. We are pioneering the convergence of immunology and RNA science to build a clinical-stage portfolio of products, starting with the significant unmet needs of cancer patients. We are pleased that such high-quality investors have joined with us to accelerate this effort.” — Daniel Getts, Ph.D., Chief Executive Officer of Myeloid “Hatteras focuses on investments in cutting-edge companies that are disrupting the status quo and accelerating the pace of innovation. We are highly encouraged by the innovation, execution and clinical development progress demonstrated by Myeloid. We are proud to support this field-leading Company through its next phase of growth and are optimistic that these approaches will drive a meaningful clinical outcome for patients.” — Clay B. Thorp, General Partner at Hatteras Trending on Pulse 2.0